Inovio hopes Ebola vaccine booster data can provide a shot in the arm

2023-02-02

疫苗临床1期临床结果

Inovio hopes Ebola vaccine booster data can provide a shot in the arm

Preview

来源: FierceBiotech

Inovio is in need of good news from the clinic after its early efforts to develop a COVID-19 vaccine COVID-19 vaccine ran into trouble.

A day after imposing a second round of layoffs, Inovio revealed a small data set for its Ebola vaccine booster, which the company hopes could someday also boost its fortunes.

INO-4201 was tested in a phase 1b study in 46 healthy volunteers who had previously received Merck & Co.’s Ebola vaccine Ervebo three to seven years prior. The 36 participants who received the shot responded, with boosted neutralizing titers maintained 24 weeks later.

Patients received a 1-mg dose, which was injected intradermally followed by electroportation using Inovio's Cellectra device. Cellectra is a hand-held device that uses a brief electrical pulse to allow plasmids to enter cells through temporary pores.

Inovio is working with Global Urgent and Advanced Research and Development, or GuardRX, through funding from the U.S. Defense Advanced Research Projects Agency, or DARPA, and Geneva University Hospitals. The company expects to reveal more data in a peer-reviewed journal at a later date.

The Pennsylvania biotech is in need of good news from the clinic, after its early efforts to develop a COVID-19 vaccine COVID-19 vaccine ran into trouble in 2021 while other companies got to the finish line faster. With that disappointment, Inovio's tough times continued, culminating in two rounds of layoffs, most recently on Wednesday when 11% of the workforce was let go.

In the strategic reorganization announced this week, Inovio said its lead programs were treatments for HPV-associated diseases. This includes recurrent respiratory papillomatosis candidate INO-3107 and VGX-3100 for cervical high-grade squamous intraepithelial lesions. The company is expecting data from both programs in the third quarter.

Editor's note: This story was updated at 3:06 p.m. ET on Feb. 2, 2023, to correct that Wednesday's layoffs involved 11% of staff.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构